PBAC Public Summary Documents – December 2022

Page last updated: 27 October 2023

Public Summary Documents relating to the December 2022 PBAC meeting.

• Acalabrutinib: Capsule 100 mg; Calquence® – December 2022
• Human papillomavirus 9-valent vaccine: Injection 0.5 mL, pre-filled syringe; Gardasil®9 – December 2022
• Ibrutinib: Capsule 140 mg; Imbruvica® – December 2022
• Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® – December 2022

• Zoledronic acid: Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL; APO-Zoledronic Acid® - December 2022 – July 2023

The following Public Summary Document was finalised out-of-session in December 2022.

• Empagliflozin: Tablet 10 mg; Jardiance®

The following Public Summary Documents have been updated:

July 2022 PBAC meeting

• Trastuzumab deruxtecan: Powder for I.V. infusion 100 mg; Enhertu® – December 2022

September 2022 PBAC Intracycle meeting

• Tixagevimab and cilgavimab: Pack containing 1 vial of tixagevimab 150 mg in 1.5 mL and 1 vial of cilgavimab 150 mg in 1.5 mL; Evusheld®